Literature DB >> 25542449

Central nervous system metastasis from breast cancer.

Susan E Bates1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25542449      PMCID： PMC4294618          DOI： 10.1634/theoncologist.2014-0469

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

Review 1.  Drug transport at the blood-brain barrier and the choroid plexus.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Curr Drug Metab       Date:  2004-02       Impact factor: 3.731

2.  Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

Authors:  H J Burstein; G Lieberman; D J Slamon; E P Winer; P Klein
Journal:  Ann Oncol       Date:  2005-09-08       Impact factor: 32.976

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

Review 4.  Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.

Authors:  Chirag G Patil; Katie Pricola; J Manuel Sarmiento; Sachin K Garg; Andrew Bryant; Keith L Black
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

5.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

6.  A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

Authors:  Polly Niravath; Yee Lu Tham; Tao Wang; Angel Rodriguez; Claudette Foreman; Susan G Hilsenbeck; Richard Elledge; Mothaffar Rimawi
Journal:  Oncologist       Date:  2014-11-06

7.  Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

Authors:  Paul R Lockman; Rajendar K Mittapalli; Kunal S Taskar; Vinay Rudraraju; Brunilde Gril; Kaci A Bohn; Chris E Adkins; Amanda Roberts; Helen R Thorsheim; Julie A Gaasch; Suyun Huang; Diane Palmieri; Patricia S Steeg; Quentin R Smith
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

8.  Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.

Authors:  Aki Morikawa; David M Peereboom; Helen R Thorsheim; Ramakrishna Samala; Rajiv Balyan; Conleth G Murphy; Paul R Lockman; Ahkeem Simmons; Robert J Weil; Viviane Tabar; Patricia S Steeg; Quentin R Smith; Andrew D Seidman
Journal:  Neuro Oncol       Date:  2014-07-11       Impact factor: 12.300

9.  The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  J Neurooncol       Date:  2013-05-10       Impact factor: 4.130

Review 10.  Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.

Authors:  Agnes V Tallet; David Azria; Emilie Le Rhun; Fabrice Barlesi; Antoine F Carpentier; Antony Gonçalves; Sophie Taillibert; Frédéric Dhermain; Jean-Philippe Spano; Philippe Metellus
Journal:  Int J Mol Sci       Date:  2014-05-08       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.